title: Optimalization and cost management of lanreotide-Autogel therapy in acromegaly.
abstract: BACKGROUND
  Lanreotide-Autogel is a depot formulation of the somatostatin analog lanreotide used in the treatment of acromegaly. We investigated whether prolonging or shortening the interval between injections would offer any benefit.
  
  
  METHODS
  The interval was prolonged from once every 4 weeks to once every 6 weeks when patients (n=9) had normal IGF-I and GH concentrations. When patients (n=12) had still elevated IGF-I or GH on the maximal dose of 120 mg every 4 weeks, the interval was shortened to once every 3 weeks. Serum IGF-I and GH were measured after 12 and 24 weeks to allow for dose adaptation. Symptoms and tumor volume were evaluated at baseline and after 36 weeks.
  
  
  RESULTS
  In seven of the nine subjects with normal IGF-I and GH, the interval could be extended to 6 weeks without loosing efficacy on IGF-I (195 vs 213 microg/l; not significant, NS) and GH concentrations (1.4 vs 1.3 microg/l; NS). The weekly dose could significantly be reduced (from 23.3 to 17.8 mg; P=0.002). In only 1 of the 12 not-controlled patients, reducing the interval to once every 3 weeks induced normalization of IGF-I and GH.
  
  
  CONCLUSIONS
  In subjects whose acromegaly is well controlled using lanreotide-Autogel, prolonging the time interval between injections can often be increased 4 to 6 weeks without loss of efficacy, thereby improving the subject's comfort and reducing the cost of treatment. On the other hand, in subjects whose acromegaly is not controlled on a dose of 120 mg every 4 weeks, reducing the interval to every 3 weeks is rarely beneficial.
authors.affiliation: Department of Endocrinology, University Hospital of Antwerp, Wilrijkstraat 1, B-2650 Antwerp, Belgium. pascale.abrams@uza.be
authors.forename: Pascale
authors.initials: P
authors.lastname: Abrams
authors.forename: Orsalia
authors.initials: O
authors.lastname: Alexopoulou
authors.forename: Roger
authors.initials: R
authors.lastname: Abs
authors.forename: Dominique
authors.initials: D
authors.lastname: Maiter
authors.forename: Johan
authors.initials: J
authors.lastname: Verhelst
mesh_terms: D000172:Acromegaly / Q000188:drug therapy* / Q000191:economics*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003362:Cost-Benefit Analysis / Q000379:methods; D003365:Costs and Cost Analysis / Q000379:methods; D004334:Drug Administration Schedule; D005260:Female; D005782:Gels; D006801:Humans; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000008:administration & dosage* / Q000191:economics*; D011446:Prospective Studies; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics
chemical_list: D005782:Gels; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin